News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Exscientia enters strategic drug discovery collaboration with GSK

Exscientia enters strategic drug discovery collaboration with GSK05/07/2017Pre-clinical collaboration focused on up to 10 targets nominated by GSKExscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI enabled platform and combine this with the expertise of GSK, in order to discove


2. Immunocore and MEPC announce significant laboratory expansion at Milto

Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK10/07/2017Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, and MEPC Limited (MEPC), a leading property developer and asset manager, announced today that Immunocore will expand its operations at Milton Park in Oxfordshire initially by a further 53,000 square feet (sq ft). The new purpose-built research lab


3. PCI Reinforces Ongoing Commitment to Serialization in Response to Dela

PCI Reinforces Ongoing Commitment to Serialization in Response to Delayed Enforcement of FDA Deadline12/07/2017Last month, the FDA gave the pharmaceutical supply chain a further year to prepare for the DSCSA requirements, announcing a postponed deadline of November 2018 by when pharmaceutical manufacturers must include product identifiers on all prescription drug packages and cases.The FDA announcement was widely anticipated and welcomed by key stakeholders across the pharmaceutical manufacturin


4. Canada Pension Plan Investment Board acquires 50% stake in Milton Park

Canada Pension Plan Investment Board acquires 50% stake in Milton Park from Hermes14/07/2017Located in the Thames Valley region of the U.K., Milton Park accommodates leading global science and technology companies as well as emerging businesses, including a number of spin-off organisations from the nearby University of Oxford. At 250 acres, Milton Park is one of Europe’s largest and most successful integrated business, science and technology parks and home to over 250 organisations employi


5. Oxford BioMedica Announces Refinancing of Debt Facility

Oxford BioMedica Announces Refinancing of Debt Facility30/06/2017Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased to announce it has today completed a new $55 million debt facility with Oaktree Capital Management – Strategic Credit Strategy (“Oaktree”). The facility has been used to redeem the existing debt facility.The loan is repayable no later than 29 June 2020 although it may be re



Page 27 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2018